Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

Blood

Volumn 102, Issue 5, 2003, Pages 1578-1582

  Wadleigh, Martha ^b   Richardson, Paul G ^b   Zahrieh, David ^b   Lee, Stephanie J ^b   Cutler, Corey ^b   Ho, Vincent ^b   Alyea, Edwin P ^b   Antin, Joseph H ^b   Stone, Richard M ^b   Soiffer, Robert J ^b   DeAngelo, Daniel J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOTRANSPLANTATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CAUSE OF DEATH; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG FATALITY; DRUG INDUCED DISEASE; FEMALE; HIGH RISK PATIENT; HUMAN; LIVER DYSFUNCTION; LIVER ENZYME ABNORMALITY; LIVER TOXICITY; LOGISTIC REGRESSION ANALYSIS; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STEM CELL TRANSPLANTATION; UNITED STATES; VEIN OCCLUSION;

EID: 0042442407     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-01-0255     Document Type: Article

References (34)

1. Sievers E, Larson R, Stadtmauer E, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244-3254.
2. Sievers E, Larson R, Estey E, et al. Final report ol prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin followed by hematopoietic stem cell transplantation [abstract]. Blood. 2002;100:89a.
3. Rajvanshi P, Shulman H, Sievers E, et al. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99:10-14.
4. Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92:406-413.
5. McDonald G, Hinds M, Fisher L, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255-267.
6. Bearman SI, Anderson GL, Mori M, et al. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol. 1993;11:1729-1736.
7. Sievers E, Larson R, Estey E, et al. Low incidence of hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin: relationship to hematopoietic stem cell transplantations [abstract]. Blood. 2000;96:206b.
8. Dulley F, Kanfer E, Appelbaum F, et al. Venocclusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation. Transplantation. 1987;43:870-873.
9. Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood. 1998;92:3599-3604.
10. McDonald G, Sharma P, Matthews D, et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4:116-122.
11. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778-783.
12. Richardson P, Guinan E. Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta Haematol. 2001;106:57-68.
13. Bearman S. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 1995;85:3005-3020.
14. Shulman H, Fisher L, Schoch H, et al. Venoocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology. 1994;19:1171-1180.
15. DeLeve LD, Ito Y, Bethea NW, et al. Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome. Am J Physiol Gastrointest Liver Physiol. 2003; 284:G1045-G1052.
16. Wang X, Kanel GC, DeLeve LD. Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat. Hepatology. 2000;31:428-434.
17. DeLeve LD. Hepatic venoocclusive disease: a major complication of hematopoietic stem cell transplantation in cancer patients. Tumori. 2001; 87(suppl):S27-S29.
18. Ikemoto N, Kumar R, Ling T, et al. Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove. Proc Natl Acad Sci U S A. 1995;92:10506-10510.
19. Bross P, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490-1496.
20. Stadtmauer E, Larson R, Sievers E, et al. Analysis of predisposing factors for hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (mylotarg, CMA-676) [abstract]. Blood. 2001;98:313a.
21. Muench M, Cupp J, Polakoff J, et al. Expression of CD33, CD38, and HLA-DR on CD34+ human fetal liver progenitors with a high proliferative potential. Blood. 1994;83:3170-3181.
22. Golden-Mason L, Curry M, Nolan N, et al. Differential expression of lymphoid and myeloid markers on differentiating hematopoietic stem cells in normal and tumor-bearing adult human liver. Hepatology. 2000;31:1251-1256.
23. LaMarr W, Yu L, Nicolaou K, et al. Supercoiling affects the accessibility of glutathione to DNA-bound molecules: positive supercoiling inhibits calicheamicin-induced DNA damage. Proc Natl Acad Sci U S A. 1998;95:102-107.
24. Ringden O, Remberger M, Lehmann S, et al. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplant. 2000;25:993-996.
25. Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood. 2002;100:1977-1983.
26. Chopra R, Eaton J, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol. 2000;111:1122-1129.
27. Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92:737-744.
28. Abecasis MM, Conceicao Silva JP, Ferreira I, et al. Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;23:843-846.
29. Richardson P, Guinan E. The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br J Haematol. 1999;107:485-493.
30. Bianchi G, Barone D, Lanzarotti E, et al. Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Eur J Pharmacol. 1993;238:327-334.
31. Bracht F, Schror K. Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. Biochem Biophys Res Commun. 1994;200:933-937.
32. Falanga A, Marchetti M, Vignoli A, et al. Impact of defibrotide on the fibrinolytic and procoagulant properties of endothelial cell macro- and microvessels [abstract]. Blood. 2000;96:53a.
33. Richardson P, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100:4337-4343.
34. McDonald GB. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (mylotarg(r)). Clin Lymphoma. 2002;2(suppl 1):S35-S39.